Valuation: Inventiva

Market Cap 790M 882M 729M 660M 1.23B 84.03B 1.25B 8.7B 3.47B 43.98B 3.31B 3.24B 139B P/E 2026 *
-4.87x
P/E 2027 * -7.12x
Enterprise Value 654M 730M 603M 546M 1.02B 69.48B 1.04B 7.19B 2.87B 36.36B 2.74B 2.68B 115B EV / Sales 2026 *
127x
EV / Sales 2027 * 160x
Free-Float
85.11%
Yield 2026 *
-
Yield 2027 * -
1 day-2.84%
1 week+6.21%
Current month-1.37%
1 month-1.37%
3 months-17.20%
6 months-24.59%
Current year-17.62%
1 week 3.16
Extreme 3.165
3.44
1 month 2.57
Extreme 2.57
3.44
Current year 2.57
Extreme 2.57
6.2
1 year 2.57
Extreme 2.57
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 30/09/2025
Director of Finance/CFO 59 21/04/2026
Chief Operating Officer - 30/08/2026
Director TitleAgeSince
Director/Board Member 76 31/01/2017
Director/Board Member 63 26/05/2019
Director/Board Member 52 30/04/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/01/26 Others

Executive/Senior Manager

50,000 0.0262%
10/01/26 Others

General Counsel

25,000 0.0131%
10/01/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-2.84%+6.21%-4.69%-9.47% 882M
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.25%+2.58%+14.24%+83.45% 56.16B
+0.83%+2.01%+13.30%+103.69% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.32%+42.73%+103.77%+88.74% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.60%-3.19%+21.21%-12.20% 23.57B
Average -0.46%+4.82%+46.73%+145.37% 39.36B
Weighted average by Cap. -0.10%+3.61%+49.33%+161.07%

Financials

2026 *2027 *
Net sales 5.13M 5.73M 4.73M 4.28M 8.01M 546M 8.14M 56.49M 22.53M 286M 21.5M 21.04M 904M 2.24M 2.5M 2.07M 1.87M 3.49M 238M 3.55M 24.64M 9.83M 125M 9.38M 9.18M 395M
Net income -160M -179M -148M -134M -250M -17.03B -254M -1.76B -703M -8.91B -671M -657M -28.23B -212M -236M -195M -177M -331M -22.52B -336M -2.33B -930M -11.79B -888M -869M -37.33B
Net Debt -137M -153M -126M -114M -214M -14.54B -217M -1.51B -601M -7.61B -573M -561M -24.11B -432M -483M -399M -361M -675M -45.96B -686M -4.76B -1.9B -24.05B -1.81B -1.77B -76.18B
Projected Income Statement - Annual - Inventiva
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
87
Date Price Change Volume
30/10/26 €3.250 -2.84% 74,617
29/10/26 €3.345 +1.36% 430,684
28/10/26 €3.300 +0.76% 542,012
27/10/26 €3.275 -2.96% 611,864
26/10/26 €3.375 +10.29% 1,020,662
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Inventiva
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.345EUR
Average target price
9.770EUR
Spread / Average Target
+192.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inventiva